DOCSLIB.ORG

Geschäftsbericht 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

350 Geschäftsbericht 2017 1668 Auszug aus dem „Apotheken-Privileg“ des Landesherren für den Unternehmensgründer FRIEDRICH JACOB MERCK: „ [Er soll die Apotheke] der ordnung gemeess mit guten frischen, zu ein= und anderen Curen dienlichen heil- samen Medicamentis und wahren also genugsamlich versehen, und damit fort und fort würklich continuiren, daß kein Mangel erscheine.“ 2018 STEFAN OSCHMANN Vorsitzender der Geschäftsleitung und CEO von Merck „ Wissenschaftliche Neu- gierde treibt uns seit 350 Jahren an. Durch sie wurden wir Techno logie- Pioniere. Und jetzt gestalten wir die digi tale Revolution mit.“ DIE ZUKUNFT SPRICHT SIMON CLARK sechs Jungforscherinnen und -forscher promoviert im Bereich Atmosphä- rische Physik an der University of Exeter. Auch in seinen YouTube- Videos geht es vor allem um physi- kalische Themen. „ Die Dinge verbessern sich nur, wenn es Leute gibt, die ver- rückte Ideen haben und etwas Neues ausprobieren.“ Treibt Merck frische Ideen voran? Die Antwort finden Sie auf Seite 10. SAMUEL CUNHA ist ein brasilianischer Parasitologe, der seine Leidenschaft für Biologie mit vielen Fans auf YouTube teilt. „ Um leidenschaftlich zu bleiben, muss man immer an die Zukunft denken, an das mögliche Ergebnis seiner Arbeit.“ Wie hält es Merck mit diesem Grundsatz? Die Antwort lesen Sie auf Seite 11. EVA AMSEN ist promovierte Biochemikerin, Autorin und Wissenschaftsvermittlerin in London. „ Für Wissen- schaftler ist es wichtig, dass sie sich nicht nur mit ihren Kollegen austauschen, sondern auch mit Menschen aus völlig anderen Bereichen – zum Bei- spiel mit Künstlern.“ Wird interdisziplinärer Austausch bei Merck gelebt? Die Antwort lesen Sie auf Seite 13. INÉS DAWSON ist promovierte Biologin in Oxford und beliebte YouTuberin. „ Forschung und Kreativität sollten Hand in Hand gehen, da nicht alle Probleme eine eindeutige Lösung haben.“ Fördert Merck Kreativität? Die Antwort finden Sie auf Seite 14. JAKOB FUTORJANSKI ist Mitbegründer und CEO von NeuroNation, einem Berliner Startup, das sich darauf spezialisiert, Lösungen für wissenschaftliches Gehirntraining zu entwickeln. „ Nur wenn wir wissen, warum wir etwas tun, können wir die großen Herausforderungen unserer Zeit meistern.“ Gilt die Maxime von Jakob auch bei Merck? Die Antwort finden Sie auf Seite 12. SIMONE STREY ist Diplom-Geographin und CEO des Startups Peat, das mit Softwarelösungen die nachhaltige Schädlings- bekämpfung in der Landwirtschaft erleichtern möchte. Das junge Unternehmen kooperierte mit dem Merck Innovation Center in Darmstadt. „ Der verantwortungsvolle Umgang mit unseren natürlichen Lebensgrund- lagen gewinnt immer mehr an Bedeutung.“ Handelt Merck verantwortungsvoll? Die Antwort finden Sie auf Seite 15. IMMER NEUGIERIG AGINE I AGINE AUCH IN DEN NÄCHSTEN 350 JAHREN Wie sieht sie aus, die Zukunft, die wir mitgestalten? Unser Magazin liefert die Antworten und feiert die Innovationskraft, die wir seit 350 Jahren unter Beweis stellen. Highlights 2017 11. Januar Merck stärkt Portfolio zur DNA- Reparatur (DDR) Wir gehen eine Lizenzvereinbarung mit Vertex Pharmaceuticals zu vier aussichtsreichen F&E-Programmen im Bereich der DNA- 23. März Reparaturmechanismen (DNA damage response, DDR) ein. Mit dem von Vertex erworbenen FDA erteilt Bavencio® Portfolio zur DNA-Reparatur haben wir unsere beschleunigte Zulassung für seltenen eigene DDR-Plattform ergänzt und uns als aggressiven Hautkrebs ein Hauptakteur in diesem Bereich positioniert. Die US-amerikanische Arzneimittel- behörde genehmigt erstmals den Verkauf eines Krebsmittels zur Behandlung des metastasierten Merkelzellkarzinoms. 12. Januar Kooperation mit Palantir zu Big Data Wir wollen die Datenanalysefähigkeiten des US-Unternehmens Palantir nutzen und 9. Mai Arzneimittel schneller entwickeln, vermarkten und bereitstellen. Dies könnte zukünftig Bavencio® in den USA beschleunigt auch zur Entwicklung völlig neuer Therapie- gegen Blasenkrebs zugelassen optionen für Patienten beitragen. Im Noch keine zwei Monate sind vergangen, ersten Schritt wird Merck die Technologie und schon erhält Bavencio® die nächste FDA- von Palantir im Bereich der Krebstherapie Zulassung – für die Behandlung von und Patientenversorgung einsetzen, später Patienten mit lokal fortgeschrittenem oder kann dies dann in anderen Unternehmens- metastasiertem Urothelkarzinom. teilen entsprechend zum Einsatz kommen. Highlights 2017 25. August Europäische Kommission gibt grünes Licht für Mavenclad® Mavenclad® (Cladribin-Tabletten) wird in Europa für MS-Patienten zugelassen. Mavenclad® ist die erste zugelassene orale Kurzzeitbehandlung für schubförmige Multiple Sklerose mit hoher Krankheitsaktivität. 21. Juli Performance Materials weiht neues Anwendungslabor in Schanghai ein Wir eröffnen ein Applikationslabor in China, mit dem wir den umfassenden maßgeschneiderten Service zu unseren Qualitätsprodukten liefern. So können wir auch effektiv die Zusammenarbeit mit unseren Kunden für neue Anwendungen, Formulierungen und Rezepturen suchen und fördern. 31. August Wir bringen Seoul zum Leuchten Auf der ersten „Seoul Biennale of Architecture and Urbanism“ stellen wir zusammen mit unseren Kollaborationspartnern OLEDWorks, OPVIUS und Kolon ein neues gewebeartiges Fassadenkonzept vor, das die beiden Technologien OPV (organische Photovoltaik) und OLED (organische Leuchtdioden) kombiniert. 3. August Patent für CRISPR-Technologie 1. September Das Europäische Patentamt erteilt Merck das Patent für seine CRISPR-Technologie zum Einsatz in Merck veräußert Biosimilars-Geschäft einem Genomintegrationsverfahren für eukaryo- Der Verkauf des Biosimilars-Geschäfts an Fresenius, tische Zellen. Merck erhielt 2017 ähnliche Patente von der am 1. September bekannt gegeben wird, steht im zuständigen Behörden in Australien, Kanada und Einklang mit unserer Strategie, im Unternehmens- Singapur. bereich Healthcare den Fokus auf die Pipeline innova- tiver Arzneimittel in Onkologie, Immunonkologie und Immunologie zu legen. Merck erhält eine Voraus- zahlung in Höhe von 156 Mio. €, Meilenstein- zahlungen von bis zu 500 Mio. € sowie Lizenzzahlungen auf potenzielle Produktumsätze. 21. September EU-Zulassung für Bavencio® für Merkelzellkarzinom Die Europäische Kommission erteilt unserem Krebsmedikament Bavencio® die Zulassung für den seltenen und aggressiven Hautkrebs-Typ. 5. September Merck prüft strategische Optionen für Consumer-Health-Geschäft Wir bereiten strategische Optionen für Consumer Health vor. Diese beinhalten den voll- ständigen oder teilweisen Verkauf sowie strategische Partnerschaften. Damit wollen wir uns weiter auf unsere innovationsgetriebene Biopharma- Pipeline fokussieren und leiten die nächste Stufe der erfolgreichen Weiterentwicklung des Consumer- Health-Geschäfts ein. 23. Oktober Merck eröffnet neues Life-Science- Zentrum in Burlington, USA Wir eröffnen unser neues Life-Science-Zentrum in Burlington im Großraum Boston, USA – und stärken damit unsere Präsenz in dieser wichtigen globalen Wissenschaftsregion. Die neue Einrichtung dient als regionales Zentrum für wissenschaftlichen Fort- schritt und die Zusammenarbeit mit Kunden. Der Großraum Boston spielt dabei eine wichtige Rolle. 30. November Werk für Flüssigkristallfenster-Module in den Niederlanden eröffnet Wir eröffnen unsere neue Produktionsstätte für Flüssigkristallfenster-Module. Sie steht im 12. September niederländischen Veldhoven bei Eindhoven. Mit der Investition von rund 15 Mio. € setzen wir Debüt auf der IAA den Weg fort, unsere Expertise als Markt- Auf der wichtigsten Automesse Europas sind und Technologieführer bei Flüssigkristallen für wir erstmals mit einem eigenen Messestand Displays auf andere Anwendungen jenseits vertreten. Im Mittelpunkt unserer Präsentation: von Fernsehern, Laptops, Smartphones und Hightech-Materialien für Beleuchtung, Antennen, Tablet-PCs zu übertragen. Displays und Oberflächen. Kennzahlen 2017 MERCK- KONZERN Kennzahlen Veränderung in Mio. € 2017 2016 in Mio. € in % Umsatzerlöse 15.327 15.024 303 2,0 % Operatives Ergebnis (EBIT)1 2.525 2.481 44 1,8 % Marge (in % der Umsatzerlöse)1 16,5 % 16,5 % EBITDA1 4.282 4.415 – 133 – 3,0 % Marge (in % der Umsatzerlöse)1 27,9 % 29,4 % EBITDA pre1 4.414 4.490 – 76 – 1,7 % Marge (in % der Umsatzerlöse)1 28,8 % 29,9 % Ergebnis nach Steuern 2.610 1.633 977 59,9 % Ergebnis je Aktie (in €) 5,98 3,75 2,23 59,5 % Ergebnis je Aktie pre (in €)1 6,16 6,21 – 0,05 – 0,8 % Business Free Cash Flow1 3.318 3.318 – – 1 Nach den International Financial Reporting Standards (IFRS) nicht definiert. MERCK- KONZERN MERCK- KONZERN Umsatzerlöse EBITDA pre1 in Mio. € in Mio. € 2017 15.327 2017 4.414 2016 15.024 2016 4.490 2015 12.845 2015 3.630 2014 11.363 2014 3.388 2013 10.735 2013 3.253 1 Nach den International Financial Reporting Standards (IFRS) nicht definiert. Unternehmensbereiche Healthcare Life Science Performance Materials Inhaltsverzeichnis MAGAZIN Curious Minds 08 – 15 Junge Menschen als Impulsgeber: Sie sind Experten auf ihrem Feld, internationale Nachwuchsforscher, Gründer, Querdenker. In knappen Sätzen skizzieren sie selbstbewusst ihre Forderung an eine bessere Zukunft – die Geschäftsleitung antwortet, wie Merck daran arbeitet. Grenzenloser Forscherdrang 16 – 27 Bei Merck steht der Patient im Mittelpunkt. Deshalb investieren wir hohe Summen in neue Therapien – zum Beispiel zur besseren Behandlung von Krebs oder Multipler Sklerose (MS). In unseren Forschungs- und REPORT Entwicklungszentren in Darmstadt, Boston, Peking und Tokio vernetzen rund 3.000 Mitarbeiter ihre welt- weiten Aktivitäten zum Wohl der Patienten. An die Aktionäre 42 – 54 Neue Wege, Krankheiten
Recommended publications
  • Certificate ISO 14001 From

    Certificate ISO 14001 From

    CERTIFICATE This is to certify that Merck KGaA Frankfurter Strasse 250 64293 Darmstadt Germany with the organizational units/sites as listed in the annex has implemented and maintains an Environmental Management System. Scope: Development, production and distribution of pharmaceuticals, chemical products and analytical systems. Through an audit, documented in a report, it was verified that the management system fulfills the requirements of the following standard: ISO 14001 : 2015 Certificate registration no. 005356 UM15 Valid from 2020-12-17 Valid until 2023-12-16 Date of certification 2020-11-18 DQS GmbH Markus Bleher Managing Director Accredited Body: DQS GmbH, August-Schanz-Straße 21, 60433 Frankfurt am Main, Germany 1 / 19 Annex to certificate Registration No. 005356 UM15 Merck KGaA Frankfurter Strasse 250 64293 Darmstadt Germany Location Scope 005356 Development, production and distribution of Merck KGaA pharmaceuticals, chemical products and Frankfurter Straße 250 analytical systems. 64293 Darmstadt Including: Real Estate GmbH Merck Performance Materials Germany GmbH Merck Healthcare KGaA With regional offices at: Roesslerstrasse 96 64293 Darmstadt Waldstrasse 3 64331 Weiterstadt 450237 Merck S.A. Production and distribution of pharmaceuticals Estrada dos Bandeirantes, 1099 and chemical products. Rio de Janeiro - RJ 22710-571 Brazil 450240 Merck Serono SA Production and distribution of Zone Industrielle de l´Ouriettaz pharmaceuticals. 1170 Aubonne Switzerland 450325 Merck Serono SA Development and production of Corsier-sur-Vevey pharmaceuticals. Rte de Fenil 25 1804 Fenil-sur-Vevey Switzerland This annex (edition: 2020-11-18) is only valid in connection with the above-mentioned certificate. 2 / 19 Annex to certificate Registration No. 005356 UM15 Merck KGaA Frankfurter Strasse 250 64293 Darmstadt Germany Location Scope 450241 Merck & Cie Production of chemical products.
  • Annual Report 2017 DISCLAIMER

    Annual Report 2017 DISCLAIMER

    350 Annual Report 2017 DISCLAIMER Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany, operate as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Performance Materials. To reflect such fact and to avoid any misconception of the reader of the publication certain logos, terms and names of businesses of the publication have been substituted or additional descriptions have been added. This version of the publication, therefore, slightly deviates from the otherwise identical version of the publication provided outside the United States and Canada. 1668 Excerpt from the “Pharmacy Privilege” issued by the ruling court to the company founder FRIEDRICH JACOB MERCK: “ [He shall run the pharmacy] ensuring that it is properly stocked with good, freshly prepared medicinal products at all times so as to cure ailments and prevent ill health.” 2018 STEFAN OSCHMANN Chairman of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany “ Scientific curiosity has been a major driver of our success for 350 years. It has enabled us to pioneer new technologies. And now we are helping to shape the digital revolution.” THOUGHTS ON THE FUTURE SIMON CLARK Six young researchers is a PhD student in climate physics at the University of Exeter. His YouTube videos also mainly address topics in physics. “ Things only improve if there are people who have crazy ideas and try out something new.” Do we drive fresh ideas? Find the answer on page 10. SAMUEL CUNHA is a Brazilian parasitologist who shares his passion for biology with numerous followers on YouTube.
  • Merck Annual Report 2009

    Merck Annual Report 2009

    More information inside the cover: Business development 2000 – 2009 Merck CONTENTS Annual Report 2009 Publication contributors Published on February 23, 2010 by Merck KGaA, Corporate Communications Frankfurter Strasse 250, 64293 Darmstadt, Germany Tel.: +49 (0) 6151-72 0, fax: +49 (0) 6151-72 5577 E-mail: [email protected] Website: www.merck.de Concept, design and typesetting: XEO GmbH, Düsseldorf, Germany Annual Report 2009 Photographs: Pages 6, 10 and 11: Catrin Moritz, Essen; Pages 1, 2, 4, 35, 51, 57, and 63: Reinhard Koslowski, Düsseldorf Printing: Franz Kuthal GmbH & Co. KG, Mainaschaff, Germany Paper: FSC-certified “heaven 42” by Scheufelen W 840 539 350210 www.merck.de Contents Contents COMPANY BUSINESS DEVELOPMENT 2000 – 2009 2 The history of Merck This overview may include historically adjusted values in order to ensure comparability with 2009. 3 Becoming a global, publicly listed company 4 Merck today 4 The future Change vs. 2008 € million 2000 2001 2002 2003 2004 2005 20061 20071 2008 2009 in % Total revenues 2 6,910 7,721 7,521 7,364 6,017 5,887 4,485 7,081 7,590 7,747 2.1 TO OUR SHAREHOLDERS Pharmaceuticals 3,047 3,484 3,265 3,458 3,601 3,905 2,338 4,900 5,456 5,812 6.5 6 Letter from Karl-Ludwig Kley Merck Serono 1,941 2,228 1,850 1,546 1,619 1,817 1,938 4,480 5,014 5,345 6.6 10 Executive Board Generics 3 790 936 1,096 1,585 1,625 1,712 – – – – – Consumer Health Care 299 320 319 327 357 376 400 420 442 467 5.7 3 MANAGEMENT REPORT Imaging 17 – – – – – – – – – – Chemicals 1,679 1,729 1,791 1,707 1,696 1,906 2,113 2,152 2,127
  • Merck Serono the Biopharma Division of Merck

    Merck Serono the Biopharma Division of Merck

    Merck Serono The Biopharma Division of Merck September 16, 2014 Merck Our aspiration is to make great things happen Merck is the oldest pharmaceutical and chemical company in the world founded in 1668 in Darmstadt, Germany Merck is a publicly listed company on the DAX at the Frankfurt Stock exchange. The Merck family holds 70% of the shares Total Revenues : €11 billion in 2013 EBITDA Pre : €3.25 billion Around 38,000 employees in 66 countries 2 Our History Merck was founded by Friedrich Jacob Merck (1621-1678) when he acquired the Angel Pharmacy (Engel-Apotheke) in 1668 Heinrich Emanuel Merck (1794–1855) begins production on an industrial scale Merck and the US pharmaceutical company Merck, Sharp & Dohme have been two independent companies since 1917. Today, we are Merck worldwide (except for Canada and the US where we are known as EMD). 3 Our Corporate Structure Merck Group Merck Consumer Performance Merck Serono Health Materials Millipore • Oncology • Everyday health • Liquid Crystals • BioScience • ImmunoOncology protection • Pigments • Lab Solutions • Immunology/NDD • Women‘s and & Cosmetics • Process Solutions • Fertility children‘s health • Endocrinology & • Cough and cold General Medicine Biosimilars Allergopharma Pharma Business Merck Serono at a Glance We operate under the Group: Largest division of Merck name EMD Serono in Established: January 5, 2007 North America Business: Biopharmaceuticals Employees: ~15,000 Total Revenues: €6.3 billion in 2013 Headquarters: Darmstadt, Germany Global reach: Products commercialized in 150
  • 'No Free Lunch'

    'No Free Lunch'

    11-12/2013 December Markets and Companies Information Technology The Middle East and China THE NEWSPAPER FOR THE Adaptability is more important are catching up to the than ever as the fourth industrial chemical-producing West. CHEMICAL AND revolution takes off. Page 5 LIFE SCIENCE MARKETS Page 9 N EWSFLOW Markets and Companies: ‘No Free Lunch’ Merck KGaA offers £1.6 billion for AZ Materials. Bjørn Lomborg on the Give and Take in Greenhouse Gas Reduction Allessa to cut a third of its work- force. New Thinking – Bjørn Lomborg plants over a 10-year period, be- tray the fact that there is no sense might not be a household name in DuPont says it will spin off its Per- of economic reality. We are not the chemical industry, but the mention formance Chemicals unit. going to cut carbon emissions sig- of his name in environmental activist nificantly, as long as it is very, very costly.” EU Commissioner demands unified circles seems to provoke one of two framework for shale gas in Europe. reactions: adoration or distain. Lom- Lomborg On The Energy Transition borg, a Danish academic who rose to China is looking for new targets for The 2011 Fukushima disaster its abundant fuel. notoriety in 2001 with his controversial rocked many countries using nu- book “The Skeptical Environmentalist,” clear power to the core; it seemed Dow gears up to sell its Chlor-Alkali that no one was more chilled than can be found on a handful of top 50 or and Epoxy units. German Chancellor Angela Merkel top 100 lists for the world’s top intel- and her reigning party of Christian More on Pages 2-8 ▶ Democrats.
  • Acta Archive Indexes Directory

    Acta Archive Indexes Directory

    VOLUME 50, NO. 1 | 2017 ALDRICHIMICA ACTA Acta Archive Indexes • Chronological • Affiliations 4-Substituted Prolines: Useful Reagents in Enantioselective HIMICA IC R A Synthesis and Conformational Restraints in the Design of D C L T Bioactive Peptidomimetics A A • Authors • Painting Clues Recent Advances in Alkene Metathesis for Natural Product Synthesis—Striking Achievements Resulting from Increased 1 7 9 1 Sophistication in Catalyst Design and Synthesis Strategy 68 20 • Titles The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada. Chronological YEAR Vol. No. Authors Title Affiliation 1968 1 1 Buth, William F. Fragment Information Retrieval of Structures Aldrich Chemical Co., Inc. 1 Bader, Alfred Chemistry and Art Aldrich Chemical Co., Inc. 1 Higbee, W. Edward A Portrait of Aldrich Chemical Company Aldrich Chemical Co., Inc. 2 West, Robert Squaric Acid and the Aromatic Oxocarbons University of Wisconsin at Madison 2 Bader, Alfred Of Things to Come Aldrich Chemical Co., Inc. 3 Koppel, Henry The Compleat Chemists Aldrich Chemical Co., Inc. 3 Biel, John H. Biogenic Amines and the Emotional State Aldrich Chemical Co., Inc. 4 Biel, John H. Chemistry of the Quinuclidines Aldrich Chemical Co., Inc. Warawa, E.J. 4 Clark, Anthony M. Dutch Art and the Aldrich Collection Aldrich Chemical Co., Inc. 1969 2 1 May, Everette L. The Evolution of Totally Synthetic, Strong Analgesics National Institutes of Health 1 Anonymous Computer Aids Search for R&D Chemicals Reprinted from C&EN 1968, 46 (Sept. 2), 26-27 2 Hopps, Harvey B. The Wittig Reaction Aldrich Chemical Co., Inc. Biel, John H.
  • MERCK Kgaa DARMSTADT, GERMANY

    MERCK Kgaa DARMSTADT, GERMANY

    MERCK KGaA DARMSTADT, GERMANY Annual Financial Statements 2016 DISCLAIMER Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany, operate as EMD Serono in Healthcare, MilliporeSig- ma in Life Science and EMD Performance Materials. To reflect such fact and to avoid any misconception of the reader of the publication certain logos, terms and names of businesses of the publication have been substituted or additional descriptions have been added. This version of the publication, therefore, slightly deviates from the otherwise identical version of the publication provided outside the United States and Canada. For nearly 350 years, curious people at our company have been bringing ideas to life. As a global science and technology company, a passion for research and discovery is our most valuable resource. With our three business sectors, namely Healthcare, Life Science and Performance Materials, we improve the quality of life of patients, in- crease the success of our customers, and offer solutions for diverse challenges. Curiosity is and remains our strongest driving force for future-oriented innovations. Annual Financial Statements 3 Combined Management Annual Financial Statements Report 112 – 158 03 – 110 112 Balance Sheet as of December 31, 2016 113 Income Statement from the period 003 Fundamental Information about the Group from January 1 to December 31, 2016 003 The Group 114 Notes to the Annual Financial Statements 010 Objectives and strategies 115 Notes to the Balance Sheet 016 Internal Management System 125 Notes to the Income Statement 020 Corporate Responsibility 129 Other Disclosures 028 Research and development 132 Members of the Executive Board of Merck KGaA, 040 People Darmstadt, Germany 133 Supervisory Board 046 Report on Economic Position 134 Disclosures in accordance with section 160 (1) no.
  • Single Entity Report Merck Kgaa, Darmstadt, Germany

    Single Entity Report Merck Kgaa, Darmstadt, Germany

    ANNUAL FINANCIAL STATEMENTS DISCLAIMER Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany, operate as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Performance Materials. To reflect such fact and to avoid any misconception of the reader of the publication certain logos, terms and names of businesses of the publication have been substituted or additional descriptions have been added. This version of the publication, therefore, slightly deviates from the otherwise identical version of the publication provided outside the United States and Canada. Table of Contents Annual Financial Statements Combined Annual Financial Management Report Statements 6 Fundamental Information about the 127 Balance Sheet as of December 31, 2019 Group 128 Income Statement for the period from January 1 to 6 The Group December 31, 2019 14 Strategy 129 Statement of Changes in Fixed Assets 21 Internal Management System 130 Notes as of December 31, 2019 27 Corporate Responsibility 133 Notes to the Balance Sheet 37 Research and Development 141 Notes to the Income Statement 49 People 145 Other Disclosures 57 Report on Economic Position 148 Members of the Executive Board of Merck KGaA, Darmstadt, Germany 57 Macroeconomic and Sector-Specific Environment 149 Members of the Supervisory Board of Merck KGaA, Darmstadt, Germany 60 Review of Forecast against Actual Business Developments 151 Disclosures in accordance with section 160 (1) no. 8 of the German Stock Corporation Act (AktG)

  • Key Figures for 2019

    Draft as of December 20. PDF version for illustrative purposes, report will be published online. ANNUAL REPORT 2 Key Figures for 2019 MERCK GROUP Key figures Change € million 2019 2018 € million % Net sales 16,152 14,836 1,315 8.9% Operating result (EBIT)1 2,120 1,727 393 22.8% Margin (% of net sales)1 13.1% 11.6% EBITDA1 4,066 3,528 539 15.3% Margin (% of net sales)1 25.2% 23.8% EBITDA pre1 4,385 3,800 585 15.4% Margin (% of net sales)1 27.1% 25.6% Profit after tax 1,324 3,396 -2,072 -61.0% Earnings per share (in €) 3.04 7.76 -4.72 -60.8% Earnings per share pre (€)1 5.56 5.10 0.46 9.0% Business free cash flow1 2,732 2,508 224 8.9% 1Not defined by International Financial Reporting Standards (IFRSs). MERCK GROUP MERCK GROUP Net sales EBITDA pre1 € million € million 1 Not defined y International Financial Reporting Standards (IFRSs). Owing to the altered expectations in terms of the impact of the Covid-19 pandemic, some chapters of this Annual Report were updated on May 12, 2020. The respective text passages are marked in magenta. Table of Contents Annual Report To Our Shareholders Corporate Governance 5 Letter from Stefan Oschmann 136 Capital Structure and Corporate Bodies of Merck KGaA 8 The Executive Board 137 Statement on Corporate Governance including Compensation Report 9 Merck Shares 167 Report of the Supervisory Board 170 Objectives of the Supervisory Board with respect to Its Composition and Profile of Skills and Expertise Combined Consolidated Management Report Financial Statements 12 Fundamental Information about the 174 Consolidated
  • Annual Financial Statements TABLE of CONTENTS Annual Financial Statements

    Annual Financial Statements TABLE of CONTENTS Annual Financial Statements

    Annual Financial Statements TABLE OF CONTENTS Annual Financial Statements Combined Annual Financial Management Report Statements 4 Fundamental Information 140 Balance Sheet as of December 31, 2020 about the Group 141 Income Statement for the period 4 The Group from January 1 to December 31, 2020 16 Strategy 142 Statement of Changes in Fixed Assets 25 Internal Management System 143 Notes for the fiscal year 2020 31 Sustainability 147 Notes to the Balance Sheet 40 Research and Development 157 Notes to the Income Statement 57 People 161 Other Disclosures 165 Members of the Executive Board 67 Report on Economic Position of Merck KGaA, Darmstadt, Germany 67 Macroeconomic and 166 Members of the Supervisory Board Sector-Specific Environment of Merck KGaA, Darmstadt, Germany 71 Review of Forecast 168 Disclosures in accordance with against Actual Business Developments section 160 (1) no. 8 of the German 79 Course of Business and Economic Position Stock Corporation Act (AktG) 79 Group 170 List of Shareholdings of Merck KGaA, Darmstadt, Germany, as of December 31, 2020 89 Healthcare 194 Reproduction of the Independent Auditor’s 95 Life Science Report 99 Performance Materials 201 Responsibility Statement in accordance 103 Corporate and Other with section 264 (2) sentence 3 HGB and section 289 (1) sentence 5 HGB 104 Report on Risks and Opportunities 202 Report of the Supervisory Board 121 Report on Expected Developments 206 Financial Calendar 126 Report in accordance with Section 315a (1) of the German Commercial Code (HGB) 129 Additional Information
  • Annual Report 2017

    Annual Report 2017

    350 Annual Report 2017 1668 Excerpt from the “Pharmacy Privilege” issued by the ruling court to the company founder FRIEDRICH JACOB MERCK: “ [He shall run the pharmacy] ensuring that it is properly stocked with good, freshly prepared medicinal products at all times so as to cure ailments and prevent ill health.” 2018 STEFAN OSCHMANN Chairman of the Executive Board and CEO of Merck “ Scientific curiosity has been a major driver of our success for 350 years. It has enabled us to pioneer new technologies. And now we are helping to shape the digital revolution.” THOUGHTS ON THE FUTURE SIMON CLARK Six young researchers is a PhD student in climate physics at the University of Exeter. His YouTube videos also mainly address topics in physics. “ Things only improve if there are people who have crazy ideas and try out something new.” Does Merck drive fresh ideas? Find the answer on page 10. SAMUEL CUNHA is a Brazilian parasitologist who shares his passion for biology with numerous followers on YouTube. “ To stay passionate, we always have to think of the future,of the poten- tial result of our work.” What does Merck think of this principle? Find the answer on page 11. EVA AMSEN is a biochemist, writer and science communicator based in London. “ For scientists it is important to exchange ideas not only with their colleagues, but also with people from totally different fields – for example, with artists.” Does Merck practice interdisciplinary exchange? Find the answer on page 13. INÉS DAWSON is a biologist, a PhD student at Oxford and a popular YouTube blogger.
  • Externer/Interner Brief, Telefax Für Word 2000, Merck Darmstadt

    Externer/Interner Brief, Telefax Für Word 2000, Merck Darmstadt

    Progress Report Implementation of the ten principles of the UN Global Compact Period: May 2011 to December 2012 CEO’s Declaration of continued support We at Merck take our corporate responsibility seriously − it is an integral part of our entrepreneurial approach. Responsible conduct founded on clearly defined values is a key factor in Merck nearing its 350th anniversary. We would like to continue along this path. We are therefore reaffirming our commitment to the United Nations Global Compact, which we joined in 2005. We continue to support the ten principles established by the compact, which cover human rights, labor regulations, environmental protection, and anti-corruption. One example of how we actively promote human rights is our commitment to access to health, which means facilitating access to medicines for people in developing countries. After all, according to Article 25 of the UN’s Universal Declaration of Human Rights, medical care is a universal human right. Being a pharmaceutical, chemical and life science company, we can contribute our expertise in a particularly meaningful manner here. For example, we are collaborating with the World Health Organization (WHO) to combat the tropical disease schistosomiasis in Africa, where we aim to help eliminate the disease by donating praziquantel tablets. In 2012, we decided to expand our commitment and increase the tablet donation tenfold, from 25 million per year to 250 million per year in the medium term. Our Praziquantel Donation Program is, however, only one of many examples of how we are implementing the principals of the Global Compact at Merck despite economically challenging times.